RA190

SKU: orb1308770

Description

RA190 is a proteasome inhibitor that acts by covalently modifying cysteine 88 on the ubiquitin receptor RPN13. This mechanism disrupts protein degradation, making it a valuable tool for studying proteasome biology, cancer research, and apoptosis in both cellular and animal models.

Research Area

Protein Biochemistry

Key Properties

• CAS Number: 1617495-03-0
• MW: 596.76
• Purity: 97.70% (May vary between batches)
• Formula: C₂₈H₂₃Cl₅N₂O₂
• SMILES: Cl.N[C@@H](Cc1ccccc1)C(=O)N1C\C(=C\c2ccc(Cl)c(Cl)c2)C(=O)\C(C1)=C/c1ccc(Cl)c(Cl)c1
• Target: Proteasome
• Solubility: DMSO:235 mg/mL (393.79 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (5.53 mM)

Bioactivity

• Target IC50:
  HeLa cells:0.15 μM
• In Vivo:
  RA190 administration profoundly reduces growth of multiple myeloma and ovarian cancer xenografts, and oral RA190 treatment retards HPV16+ syngeneic mouse tumor growth, without impacting spontaneous HPV-specific CD8+ T cell responses.
  Read more...
• In Vitro:
  Multiple myeloma (MM) lines, even those resistant to bortezomib, are sensitive to RA190 via endoplasmic reticulum stress-related apoptosis. RA190 stabilizes targets of human papillomavirus (HPV) E6 oncoprotein, and preferentially kills HPV-transformed cells.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Inhibitor, HeLa cell, Proteasome, RA 190, RA190, RA-190

Compound Identifiers

PubChem CID

126843229